Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07243171
PHASE1/PHASE2

A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity

Sponsor: Hangzhou Sciwind Biosciences Co., Ltd.

View on ClinicalTrials.gov

Summary

The aim of the study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of oral ecnoglutide tablets in Chinese participants with overweight or obesity

Official title: A Multicenter, Multiple-dose Escalation, Randomized, Double-blind, Placebo-controlled Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

84

Start Date

2025-11-18

Completion Date

2026-11-22

Last Updated

2026-01-28

Healthy Volunteers

Yes

Interventions

DRUG

ecnoglutide tablets

oral tablets

DRUG

placebo with matching dosage

oral tablets

Locations (1)

China-Japan Friendship Hospital

Beijing, Beijing Municipality, China